Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Galectin Hopes To Set Surrogate Endpoints For NASH Cirrhosis, Despite Trial Failure

Executive Summary

Failure of small NASH cirrhosis study does not present much read-through to the larger class of NASH drugs in development. Galectin hopes its ongoing Phase IIb trial will validate its galectin-3 inhibitor in a more advanced disease state than most NASH candidates are pursuing.


Related Content

NASH Drug Development Guidance Encourages Sponsors To Adopt Innovative Trial Designs
Galectin Plans To Head Into NASH Pivotal Studies Without Biopsy-Evaluated Endpoint
Galectin Offers Subgroup Approach For Struggling NASH Candidate
Endpoint Selection Could Help Determine The NASH Race
The NASH Pipeline: Replete With Targets And New Compounds
'Clean Label' For Intercept's Ocaliva In PBC Bodes Well For NASH Claim
Conatus' Liver Focus Goes Well Beyond NASH
NASH Drugs Soon May Have A Registrational Pathway, Finally
Searching For Surrogate Endpoints Requires Teamwork


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts